Document Detail

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
MedLine Citation:
PMID:  10834859     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the efficacy and safety of a loading dose regimen of three intravenous infusions with infliximab in patients with active spondyloarthropathy. METHODS: A monocentre, open-label pilot study of 21 patients with different subtypes of spondyloarthropathy was conducted. Treatment resistant patients with active disease (fulfilling inclusion criteria) received three infusions of 5 mg/kg infliximab (at weeks 0, 2, and 6). Standard clinical assessments were performed at baseline, and on days 3, 7, and 14, and from then on every two weeks. In patients who fulfilled criteria for ankylosing spondylitis, axial assessment was performed at baseline and on days 14, 42, and 84. RESULTS: In all global assessments (visual analogue scale of patient global assessment, patient pain assessment, doctor global assessment), erythrocyte sedimentation rate, and C reactive protein, a highly significant decrease could be seen already at day 3 (compared with baseline), which was maintained up to day 84. In patients with peripheral disease (n=18), tender and swollen joint count significantly decreased. In patients with axial disease (n=11), functional and disease activity indices significantly improved. Moreover in eight patients with psoriatic arthritis a significant decrease of the psoriasis area and severity index was observed. The treatment was well tolerated in all patients; no significant adverse events were seen. CONCLUSION: In this open-label pilot study of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha in patients with active spondyloarthropathy, there was a fast and significant improvement of axial and peripheral articular manifestations, without major adverse experiences.
F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Related Documents :
6987869 - Cutaneous vascular immunofluorescence in rheumatoid arthritis. correlation with circula...
11642499 - Intensive immunosuppression and autologous stem cell transplantation for patients with ...
11254239 - Subsets in psoriatic arthritis formed by cluster analysis.
6273769 - Neuromuscular transmission in rheumatoid arthritis, with and without penicillamine trea...
8081679 - The functional and psychological outcomes of juvenile chronic arthritis in young adulth...
2218429 - Distribution of gm allotypes in juvenile chronic arthritis.
24723129 - Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: imp...
12106929 - Early dysfunction and long-term improvement in endothelium-dependent vasodilation in th...
22335599 - Cxcl13 as a novel marker for diagnosis and disease monitoring in pediatric ptld.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  59     ISSN:  0003-4967     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-07-06     Completed Date:  2000-07-06     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  428-33     Citation Subset:  IM    
Ghent University Hospital, Department of Rheumatology, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antibodies, Monoclonal / administration & dosage*
Arthritis, Psoriatic / drug therapy
Drug Therapy, Combination
Evaluation Studies as Topic
Glucocorticoids / therapeutic use
Middle Aged
Patient Selection
Pilot Projects
Prednisolone / therapeutic use
Psoriasis / drug therapy
Spondylitis / drug therapy*
Spondylitis, Ankylosing / drug therapy
Statistics, Nonparametric
Treatment Outcome
Tumor Necrosis Factor-alpha / immunology*
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antibodies, Monoclonal; 0/Glucocorticoids; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 50-24-8/Prednisolone
Comment In:
Ann Rheum Dis. 2000 Jun;59(6):404-7   [PMID:  10834852 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radiographic assessment of hip osteoarthritis progression: impact of reading procedures for longitud...
Next Document:  Improved medical and surgical management of cervical spine disease in patients with rheumatoid arthr...